肺癌化疗耐药分子标志及其逆转研究  

Molecular Markers of Multidrug Resistance and Reverse in Lung Cancer

作　　者：徐萌[1] 

机构地区：[1]暨南大学附属第一医院肿瘤科,广州市510630

出　　处：《中国医院用药评价与分析》2007年第6期412-414,共3页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家自然科学基金项目(30772844);广东省自然科学基金项目(5006066)

摘　　要：目的:探讨肺癌化疗耐药分子标志及其逆转的临床与基础应用评价。方法:采用国内外相关文献,结合我们在这一领域长期研究,深入归纳与分析。结果与结论:肺癌化疗耐药主要分子标志有多药耐药基因(MDR1)表达增加,多药耐药相关蛋白(MRP)基因表达增加,谷胱甘肽解毒酶系统活性增强和线粒体凋亡途径异常,综合采用逆转耐药分子,耐药基因siRNA和中医药结合的逆转耐药策略,为彻底攻克肺癌耐药奠定坚实研究基础。OBJECTIVE： To discuss the clinical and basic application of molecular markers of multidrug resistance and its reverse in chemotherapy for lung cancer. METHODS： We conducted a detailed analysis and summery by reviewing the pertinent literatures both at home and combining our long - term study in this area. RESULTS ＆ CONCLUSION： The molecular markers of multidrug resistance in lung cancer included high expressions of MDR1 gene and MRP gene, enhanced activity of GST system, and abnormal mitochondrial apoptosis pathway. The combined use of reverse muhidrug resistance molecules, multidrug resistance gene siRNA and Traditional Chinese medicines laid a solid foundation for the study of multidrug resistance in lung cancer.

关 键 词：肺癌 多药耐药 多药耐药基因MDR1 多药耐药相关蛋白MRP 

分 类 号：R979.1[医药卫生—药品]